Get notified of page updates

This is a treatment study is for people with metastatic colorectal cancer

Clinicaltrials.gov identifier:
NCT02997228
PRINTER FRIENDLY PAGE

Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

This is a treatment study is for people with metastatic colorectal cancer

Clinicaltrials.gov identifier:
NCT02997228
PRINTER FRIENDLY PAGE
Glossary on
off

About the Study

This study is no longer recruiting people. 

 

This study is for people with colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an agent works compared with treatment using an agent alone. This study is focused on patients who are determined to be mismatch-repair deficient () or have an MSI-H diagnosis, which are commonly seen in people with .

 

This Study is Open To:

This study is no longer recruiting people. 

This Study is NOT Open To:

This study is no longer recruiting people.